nasdaq:scph
|
3796952
|
Apr 14th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 13th, 2024 11:40PM
|
Apr 13th, 2024 11:40PM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|
nasdaq:scph
|
3796952
|
Apr 13th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 12th, 2024 11:32PM
|
Apr 13th, 2024 12:05PM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|
nasdaq:scph
|
3796952
|
Apr 12th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 11th, 2024 11:38PM
|
Apr 12th, 2024 09:01AM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|
nasdaq:scph
|
3796952
|
Apr 11th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 11th, 2024 12:15AM
|
Apr 11th, 2024 11:46AM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|
nasdaq:scph
|
3796952
|
Apr 10th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 9th, 2024 11:40PM
|
Apr 10th, 2024 05:53PM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|
nasdaq:scph
|
3796952
|
Apr 9th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 8th, 2024 11:50PM
|
Apr 9th, 2024 10:35AM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|
nasdaq:scph
|
3796952
|
Apr 8th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 8th, 2024 12:22AM
|
Apr 8th, 2024 07:32PM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|
nasdaq:scph
|
3796952
|
Apr 7th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 6th, 2024 11:45PM
|
Apr 6th, 2024 11:45PM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|
nasdaq:scph
|
3796952
|
Apr 6th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 5th, 2024 11:45PM
|
Apr 5th, 2024 11:45PM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|
nasdaq:scph
|
3796952
|
Apr 5th, 2024 12:00AM
|
scPharmaceuticals
|
4.1K
|
125.00
|
Open
|
|
Apr 5th, 2024 12:28AM
|
Apr 5th, 2024 12:28AM
|
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
|
Open
|
Improving Diuresis in Heart Failure, Next Generation OPAT, Medical Countermeasure Solutions, and Heart Failure
|
Open
|
25 Mall Road, Suite 203
|
Burlington
|
MA
|
US
|
01803
|
|
scPharmaceuticals
|
|
|